

VASCADE MVP[®]

Vascular Closure for EP Procedures

0%

MAJOR COMPLICATIONS*
in 1,223 Patients in
5 EP Clinical Trials¹⁻⁵



58%

REDUCTION
in Opioid
Use¹



63%

IMPROVEMENT
in Patient
Satisfaction¹



Safe. Simple. Proven.


hospital.Haemonetics.com/vascular-closure/vascade-mvp

HAEMONETICS[®]

Safe

Early Ambulation Proven in the AMBULATE Clinical Trial¹

Prospective, Multicenter Randomized 1:1 Clinical Trial



Study Endpoints

Primary Endpoints

Time to ambulation, major access site complications

Additional Data

Patient satisfaction, use of pain medications

**3.9 hour reduction
in median time to
ambulation**

Time to Ambulation



Reduction in
Median Time to
Ambulation

Patient Satisfaction



Improvement in
Patient Satisfaction

Opioid Use



Reduction in
Opioid Use

Safety Endpoints	VASCADE MVP® System n=199 limbs	Manual Compression n=209 limbs	P Value
Major Complications ⁷	0%	0%	—
Minor Complications ⁷	1.0%	2.4%	0.45 ⁶

Simple

Designed for EP Procedures

Extravascular design

- No permanent or intraluminal implants

2 mechanisms of action

- Mechanical
- Physiological

Bioabsorbable and thrombogenic collagen plug

- Expands to fill tissue tract

Simple and easy to use

- Single operator
- No sutures or material left in vessel

Proven

Proven by EPs in AMBULATE Clinical Trial¹ and AMBULATE Same Day Discharge Clinical Studies²⁻⁵

Prospective multicenter studies of same day discharge in paroxysmal and persistent AF ablation patients

0%
MAJOR COMPLICATIONS*
in 1,223 Patients in
5 EP Clinical Trials¹⁻⁵



Using the VASCADE MVP® System

1,106



Access Sites

354



Patients

45



Investigators

14



US Centers

91.2%

Discharged the Same Day (SDD)

99.7%

SDD Success with no access site complications⁸

0%

ZERO (0) major complications⁷

Ordering Information

PRODUCT	CATALOG NUMBER	DESCRIPTION	QUANTITY
VASCADE MVP® Venous Vascular Closure System (VVCS)	800-612C-10U	6–12F Inner Diameter (15F maximum outer diameter)	1 box (10 devices per box)

The VASCADE MVP Venous Vascular Closure System (VVCS) Model 800-612C is indicated for the percutaneous closure of femoral venous access sites while reducing time to ambulation, total post-procedure time, time to hemostasis, and time to discharge eligibility in patients who have undergone catheter-based procedures utilizing 6 – 12F inner diameter (15F maximum outer diameter) procedural sheaths, with single or multiple access sites in one or both limbs.

The VASCADE MVP Venous Vascular Closure System (VVCS) Model 800-612C is also indicated for enabling same day discharge in patients who have undergone catheter-based cardiac arrhythmia ablation procedures utilizing 6-12F inner diameter (15F maximum outer diameter) procedural sheaths, with single or multiple access sites in one or both limbs.

The VASCADE MVP Venous Vascular Closure System (VVCS) should not be used in patients with a known allergy to bovine derivatives.

Hover your camera over the QR code to learn more about VASCADE MVP.



Please consult product labels and instructions for use for indications, contraindications, warnings, precautions and adverse events. See VASCADE MVP IFU 3972 Instructions for Use.

For a list of worldwide office locations and contact information, visit: www.haemonetics.com/officelocations

Learn More:

800-537-2802

CustomerServiceNA@haemonetics.com

hospital.haemonetics.com/vascular-closure/vascade-mvp

1. Natale A, et al. Venous vascular closure system versus manual compression following multiple access electrophysiology procedures: The AMBULATE Trial. JACC Clin Electrophysiol 2020; 6(1):111-124.
2. Al-Ahmad A, et al. Results from the prospective, multicenter AMBULATE-CAP trial: Reduced use of urinary catheters and protamine with hemostasis via the mid-bore venous vascular closure system VASCADE MVP following multi-access cardiac ablation procedures. J Cardiovasc Electrophysiol 2021. 32(2): 191-99.
3. AMBULATE Same Day Discharge Registry Retrospective Study: NCT04538781
- 4/5. Eldadah ZA, et al. Same-day discharge following catheter ablation and venous closure with VASCADE MVP: A post-market registry. Published online Nov 30, 2022. J Cardiovasc Electrophysiol <https://doi.org/10.1111/jce.15763>.
6. P-value by 2-sided Fisher's exact test
7. Venous access site closure-related complications per limb through follow up period
8. Did not require intervention for access site complications the next day through 15-day follow up